Company Profile

Synergen Inc (AKA: Amgen Boulder Inc)
Profile last edited on: 5/13/19      CAGE: 0E7Z2      UEI:

Business Identifier: Protein-based pharmaceuticals
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1885 33rd Street
Boulder, CO 80301
   (303) 938-6200
Location: Single
Congr. District: 02
County: Boulder

Public Profile

In December 1994, Synergen Inc (NASDAQ:SYGN) was acquired by Amgen - itself having been, in its very early days, an SBIR awardee. Post acquisition, Synergen was renamed Amgen Boulder. Before the acquisiton, having sometimes been referenced as the 'next' Amgen, the firm had been working on protein-based pharmaceuticals including ones to treat Lou Gehrig's disease, Parkinson's disease and rheumatoid arthritis. The company was dealt a major setback when it was reported that a new drug, Antril, which would have been used to fight the blood disease sepsis, had failed in tests. The drug's failure forced the company to lay off 60 percent of its work force. At the time of acqusition, the company had had five products in development which were aimed at treating inflammatory and neurological disorders. The company subsequently entered into phase three of clinical trials on two of its products, Antril and ciliary neurotrophic factor. From early dats, Synergen company had been involved in range of working relationships with other major pharmaceutical companies and that continued after the acquisition.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1990 2 NIH $550,000
Project Title: Anti-plaque proteins via genetic engineering
1989 1 NIH $50,000
Project Title: Kallikrein inhibitors by genetic engineering
1989 1 NIH $50,000
Project Title: Vaccine against haemophilus influenzae type B
1989 1 NIH $50,000
Project Title: New drug for preventing post ischemic tissue injury
1988 1 NIH $50,000
Project Title: Therapeutic clearance of complemet C5A

Key People / Management

  Gregory Abbott -- President and CEO

  Larry J Forney

  Charles H Hannum

  David Hirsh

  Robert C Thompson